743 related articles for article (PubMed ID: 12425204)
1. [Glycoprotein IIb/IIIa platelet blockers in acute myocardial infarct treated with primary coronary angioplasty].
Kala P; Poloczek M; Bocek O; Jerábek P; Neugebauer P; Kosová J; Semrád B
Vnitr Lek; 2002 Aug; 48(8):736-41. PubMed ID: 12425204
[TBL] [Abstract][Full Text] [Related]
2. Impact of preprocedural TIMI flow on myocardial perfusion, distal embolization and mortality in patients with ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb/IIIa inhibitors.
Maioli M; Zeymer U; van 't Hof AW; Gibson CM; Dudek D; Bellandi F; Noc M; Secco GG; Zorman S; Gabriel HM; Emre A; Cutlip D; Rakowski T; Gyongyosi M; Huber K; De Luca G;
J Invasive Cardiol; 2012 Jul; 24(7):324-7. PubMed ID: 22781470
[TBL] [Abstract][Full Text] [Related]
3. Increased reperfusion by glycoprotein IIb/IIIa receptor antagonist administration in case of unsuccessful and failed thrombolysis in patients with acute myocardial infarction: a pilot study.
Di Pasquale P; Sarullo FM; Cannizzaro S; Vitrano MG; Giubilato A; Scalzo S; Giambanco F; Paterna S
Ital Heart J; 2001 Oct; 2(10):751-6. PubMed ID: 11721719
[TBL] [Abstract][Full Text] [Related]
4. The impact of GP IIb/IIIa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction patients.
Lavi S; Gruberg L; Kapeliovich M; Hammerman H; Boulos M; Grenadier E; Aronson D; Markiewicz W; Beyar R
J Invasive Cardiol; 2005 Jun; 17(6):296-9. PubMed ID: 16003002
[TBL] [Abstract][Full Text] [Related]
5. A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials.
Gurm HS; Tamhane U; Meier P; Grossman PM; Chetcuti S; Bates ER
Circ Cardiovasc Interv; 2009 Jun; 2(3):230-6. PubMed ID: 20031720
[TBL] [Abstract][Full Text] [Related]
6. Platelet glycoprotein IIb/IIIa inhibition as adjunctive therapy during primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction.
Young JJ
J Invasive Cardiol; 2005 Jun; 17(6):300-1. PubMed ID: 16003003
[No Abstract] [Full Text] [Related]
7. [Adjuvant therapy with a glycoprotein IIb-IIa inhibitor (abciximab) in coronary angioplasties with a high thrombotic risk].
Matos V; Marques AM; Oliveira H; Ramos D; Lopes P; Camacho M; Gonsalves A
Rev Port Cardiol; 1998 Dec; 17(12):1001-5. PubMed ID: 9973861
[TBL] [Abstract][Full Text] [Related]
8. Safety and tolerability of abciximab in patients with acute myocardial infarction and failed thrombolysis.
Di Pasquale P; Cannizzaro S; Scalzo S; Maringhini G; Vitrano GM; Giubilato A; Giambanco F; Sarullo FM; Paterna S
Int J Cardiol; 2003 Dec; 92(2-3):265-70. PubMed ID: 14659863
[TBL] [Abstract][Full Text] [Related]
9. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
[TBL] [Abstract][Full Text] [Related]
10. [Implantation of coronary stents in reperfusion therapy in acute myocardial infarct].
Kala P; Poloczek M; Bocek O; Jerábek P; Neugebauer P; Kosová J
Vnitr Lek; 2002 Aug; 48(8):730-5. PubMed ID: 12425203
[TBL] [Abstract][Full Text] [Related]
11. Glycoprotein IIb/IIIa inhibitors during rescue percutaneous coronary intervention in acute myocardial infarction.
Gruberg L; Suleiman M; Kapeliovich M; Hammerman H; Grenadier E; Boulus M; Amikam S; Markiewicz W; Beyar R
J Invasive Cardiol; 2006 Feb; 18(2):59-62. PubMed ID: 16446517
[TBL] [Abstract][Full Text] [Related]
12. Platelet GP IIb-IIIa Receptor Antagonists in Primary Angioplasty: Back to the Future.
De Luca G; Savonitto S; van't Hof AW; Suryapranata H
Drugs; 2015 Jul; 75(11):1229-53. PubMed ID: 26177890
[TBL] [Abstract][Full Text] [Related]
13. Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials.
De Luca G; Navarese E; Marino P
Eur Heart J; 2009 Nov; 30(22):2705-13. PubMed ID: 19875386
[TBL] [Abstract][Full Text] [Related]
14. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
Adgey AA
Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518
[TBL] [Abstract][Full Text] [Related]
15. Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE).
Tricoci P; Peterson ED; Chen AY; Newby LK; Harrington RA; Greenbaum AB; Cannon CP; Gibson CM; Hoekstra JW; Pollack CV; Ohman EM; Gibler WB; Roe MT
Am J Cardiol; 2007 May; 99(10):1389-93. PubMed ID: 17493466
[TBL] [Abstract][Full Text] [Related]
16. PlA(1)/PlA(2) polymorphism does not influence response to Gp IIb-IIIa inhibitors in patients undergoing coronary angioplasty.
Verdoia M; Pergolini P; Camaro C; Restifo M; Rolla R; Schaffer A; Di Giovine G; Marino P; Bellomo G; Suryapranata H; De Luca G;
Blood Coagul Fibrinolysis; 2013 Jun; 24(4):411-8. PubMed ID: 23412353
[TBL] [Abstract][Full Text] [Related]
17. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.
EPISTENT Investigators
Lancet; 1998 Jul; 352(9122):87-92. PubMed ID: 9672272
[TBL] [Abstract][Full Text] [Related]
18. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction.
Montalescot G; Barragan P; Wittenberg O; Ecollan P; Elhadad S; Villain P; Boulenc JM; Morice MC; Maillard L; Pansiéri M; Choussat R; Pinton P;
N Engl J Med; 2001 Jun; 344(25):1895-903. PubMed ID: 11419426
[TBL] [Abstract][Full Text] [Related]
19. Frequency and efficacy of glycoprotein IIb/IIIa therapy for treatment of threatened or acute vessel closure in 1332 patients undergoing percutaneous transluminal coronary angioplasty.
Haase KK; Mahrholdt H; Schröder S; Baumbach A; Oberhoff M; Herdeg C; Karsch KR
Am Heart J; 1999 Feb; 137(2):234-40. PubMed ID: 9924156
[TBL] [Abstract][Full Text] [Related]
20. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention.
Boersma E; Akkerhuis KM; Théroux P; Califf RM; Topol EJ; Simoons ML
Circulation; 1999 Nov; 100(20):2045-8. PubMed ID: 10562258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]